Angiogenesis inhibitors compared to placebo for the treatment of persistent, recurrent, or metastatic cervical cancer
Patient or population: adult women (aged 18 years or over) with persistent, recurrent, or metastatic cervical cancer Settings: hospital Intervention: treatment with angiogenesis inhibitors Comparison: standard care, placebo or none.
Outcomes	Illustrative comparative risks*		Relative effect (95% CI)	No of participants (studies)	Quality of evidence (GRADE)	Comment
	Assumed risk	Corresponding risk
Overall survival Follow‐up: 48 months
Total adverse events
Adverse events Gastrointestinal perforations and fistulae
Adverse events Haemorrhage
Adverse events Thromboembolic events
Adverse events Hypertension
Economic evaluation
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; HR: hazard ratio; MD: mean difference; RR: risk ratio; OR: odds ratio
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.